Stifel Remains Bullish on Tango Therapeutics (TNGX)
Tango Therapeutics, Inc. (NASDAQ:TNGX) is one of the best performing healthcare stocks so far in 2026. Stifel lifted the price target on Tango Therapeutics, Inc.
Tango Therapeutics Inc. (TNGX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 12,809,485 | $267,974,426 | +21% | 0.41% |
| 2. | Boxer Capital Aaron Davis And Christopher Fuglesang | 10,876,219 | $227,530,501 | 29.87% | |
| 3. | Farallon Capital Thomas Steyer | 9,097,411 | $190,317,838 | -31% | 1.08% |
| 4. | Woodline Partners Michael Rockefeller And Karl Kroeker | 8,000,013 | $167,360,272 | -21% | 0.63% |
| 5. | Siren L.L.C. Raymond Debbane | 5,657,105 | $118,346,637 | -31% | 3.28% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.78 | 10,000 | $37,800.00 | 31,250 | 2024-11-18 | Filing | |
| $3.62 | 10,000 | $36,200.00 | 21,250 | 2024-11-14 | Filing | |
| $6.84 | 500,000 | $3,420,000.00 | 8,198,642 | 2023-10-16 | Filing | |
| $7.07 | 750,000 | $5,302,500.00 | 7,698,642 | 2023-10-13 | Filing | |
| $6.84 | 500,000 | $3,420,000.00 | 8,198,642 | 2023-10-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.00 | 1,100 | $24,196.04 | 115,743 | 2026-05-01 | Filing | |
| $21.19 | 25,900 | $548,901.29 | 116,843 | 2026-05-01 | Filing | |
| $25.00 | 38,460 | $961,500.00 | 112,622 | 2026-04-15 | Filing | |
| $21.20 | 27,000 | $572,478.30 | 112,622 | 2026-04-01 | Filing | |
| $20.11 | 12,000 | $241,320.00 | 112,622 | 2026-03-25 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,300,620 | $278,248,970 | 2.77% | |
| 2. | 10,531,071 | $220,310,005 | 6.3% | |
| 3. | 9,905,919 | $207,231,826 | 0.01% | |
| 4. | 8,748,045 | $183,009,100 | 0% | |
| 5. | 7,266,081 | $152,006,415 | 10.7% |
News See All
10 Best Performing Healthcare Stocks So Far in 2026
She was of the view that the backdrop at present is featuring geopolitical tensions, Fed policy uncertainty, inflation concerns, and still, it is incredible that the stock market is at record highs.
10 Best Performing Stocks of Q1 2026 to Watch for Q2
On April 3, Reuters reported that in the coming week, upcoming inflation data and initial company earnings could begin to show how the Middle East war is affecting the US economy and corporate America...
Tango Therapeutics' (TNGX) Sees Cautious Analyst Optimism Following Earnings
Financial firm Mizuho raised its share price target for Tango Therapeutics Inc. (NASDAQ:TNGX) on March 11th. It slightly adjusted the target to $20 from $19 and kept an Outperform rating on the stock.
11 Best Day Trading Stocks to Buy Now
In a recent appearance on CNBC, a member of the channel's Halftime Report's Investment Committee, Joseph Terranova, discussed the ongoing volatility in the stock market stemming from the military operations...
Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX)
On March 6, Wedbush increased the firm’s price target on Tango Therapeutics Inc. (NASDAQ:TNGX) from $15 to $19 following the company’s fourth quarter financial results and corporate updates.
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds
On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026.
Tango Therapeutics (TNGX) Soars 52% on Buy Reco
Tango Therapeutics soared by 52.15 percent week-on-week, as investors took heart from a flurry of positive developments, including a “buy” recommendation for its stock and the start of a series of...
10 Stocks Investors Are Watching Closely This Week
In the fourth quarter alone, Samsara Inc. (NYSE:IOT) swung to a net income of $22 million, reversing a net loss of $11.2 million in the same quarter a year earlier.
Tango Therapeutics (TNGX) Hits All-Time High as Analyst Turns Bullish
In a market report, investment firm Stifel reaffirmed its “buy” recommendation and $15 price target for the stock.
Hedge Fund Resource Center